Gossamer Bio in Agreement with Merck for Solid Tumor Studies

Gossamer Bio said it is in a clinical collaboration agreement with Merck & Co. Inc. (MRK) to evaluate the combination of Gossamer’s investigational candidate GB1275 and Merck’s Keytruda in patients with advanced solid tumors.

Gossamer will conduct a Phase 1/2 study, Keynote-A36, in advanced solid tumors, with the Phase 1 consisting of dose escalation of three GB1275 regimens including one with Keytruda. The Phase 2 consists of expansion cohorts evaluating GB1275 in combination with Keytruda or chemotherapy.

The KEYNOTE-A36 Phase 1/2 trial is underway, enrolling patients in the U.S. and U.K. to treat solid tumor types, including pancreatic, gastric, esophageal, colorectal, prostate and triple negative breast.

Gossamer said it expects to report initial data from the Phase 1 portion of the study in the second half of 2020.

https://www.marketscreener.com/GOSSAMER-BIO-INC-54432568/news/Gossamer-Bio-in-Agreement-with-Merck-for-Solid-Tumor-Studies-29565081/